Gene editing utilizes enzymes that cut part of the DNA strand, allowing the insertion of replacement DNA. Several approaches to gene editing have been developed, the most well-known of which is CRISPR-Cas9 . It is the most accurate, quickest and least expensive method.
Developments in the gene editing space have led to valuable stocks with strong ratings emerging that are worthy of investment. However, not all of these companies are profitable. In fact, the majority are not.
Most of the gene editing stock opportunity lies in the promise of growth that will create future profitability rather than current solid fundamentals. That’s something of a problem because many companies with such a profile never fulfill their potential. So, it is wiser to identify gene editing stocks that are either currently profitable or show the potential to soon become so.
Let’s take a look at three gene editing stocks that fulfill those requirements. CRISPR Therapeutics (CRSP) CRISPR Therapeutics (NASDAQ: CRSP ) is the original developer of the predominant gene editing technology. It is very much a stock worth investing in on the basis of FDA approval of Casgevy.
The company is investing heavily to expand the market for the drug. Investments in research and development and market expansion are part of the reason that the company’s net losses more than doubled in the first quarter, reaching $116.6 million .
CRISPR Therapeutics boasts more than $2 billion in cash reserves indicating that the bus.
